Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
Ventyx Biosciences(US:VTYX) Globenewswire·2025-10-23 04:02VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a monotherapy ...